Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
On May 16, 2025, Telomir Pharmaceuticals, Inc. announced the mutual resignation of Michelle Yanez as Chief Financial Officer, Treasurer, and Secretary, effective on that date. The company appointed Alan Weichselbaum as the new Chief Financial Officer effective May 15, 2025. Mr. Weichselbaum brings over 30 years of experience in corporate finance and strategic advisory, having held senior roles on Wall Street and founded an outsourced CFO advisory firm. His extensive expertise in capital markets and investor relations is expected to play a crucial role in the company’s growth strategy.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on drug development, licensing, and potential mergers and acquisitions (M&A) opportunities. The company is committed to advancing financial and strategic objectives to support its growth.
Average Trading Volume: 169,263
Technical Sentiment Signal: Sell
Current Market Cap: $75.6M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.